Track market-moving stories before they get noisy

AeroVironment merits a buy rating due to its leadership in both drone and counter-drone solutions, despite recent share price weakness. AVAV's Switchblade franchise and counter-UAS offerings, including LOCUST and Freedom Eagle, position it for strong, scalable growth as autonomous warfare accelerates. SCAR program cancellation and related $151M impairment have pressured AVAV's stock, but core franchises are driving 30% revenue growth and margin expansion.

Key Takeaways CPRX reported phase I data supporting Agamree's potential label expansion beyond approved DMD use. CPRX said Agamree matched Emflaza's activity while showing fewer immunosuppressive biomarker effects. CPRX found no meaningful immunosuppression at lower therapeutic doses, supporting future studies. Catalyst Pharmaceuticals (CPRX - Free Report) has reported positive top-line results from an early-stage study evaluating Agamree (vamorolone) to explore additional indications beyond its currently approved use in Duchenne muscular dystrophy (DMD) patients aged two years and older.

The phase I study assessed Agamree's glucocorticoid activity, anti-inflammatory effects and immunosuppressive profile in healthy adults compared with PTC Therapeutics' (PTCT - Free Report) Emflaza (deflazacort). The findings suggest that Agamree may deliver corticosteroid benefits without the clinically meaningful immunosuppression associated with conventional corticosteroids at approved doses, potentially opening the door to additional chronic inflammatory rare disease indications. Lower immunosuppressive activity may reduce the risk of infection and immune-related adverse effects commonly associated with chronic corticosteroid use.

Under a 2023 licensing agreement with Santhera, Catalyst Pharmaceuticals holds exclusive commercialization rights for Agamree in North America for DMD as well as any future indications, while Santhera retains the right of first negotiation for new indication rights outside North America. The agreement also entitles Santhera to sales-based milestone payments and royalties across all commercialized indications, making any label expansion a potentially important value driver.

The phase I study consisted of two parts involving healthy adult volunteers. Part A was a randomized crossover study designed to assess equipotency between Agamree and PTCT's Emflaza, helping evaluate the clinical scenario in which a patient might experience differential cortisol effects when switching from Emflaza to Agamree. Part B evaluated multiple ascending doses of Agamree to determine whether clinically meaningful immunosuppression emerges at higher doses.

Year to date, Catalyst Pharmaceuticals shares have gained 34.7% compared with the industry’s 6.3% growth.

Image Source: Zacks Investment Research

CPRX’s Phase I Agamree Study Findings in DetailPart A of the phase I study enrolled 24 healthy adults who received either a single 300 mg dose of Agamree or a 0.9 mg/kg dose of Emflaza. Both therapies demonstrated expected on-target glucocorticoid receptor activity, producing comparable cortisol suppression, leukocyte redistribution and functional immune biomarker changes. Their onset of activity was also similar, occurring roughly two to four hours after dosing.

Despite comparable glucocorticoid activity, Agamree produced less pronounced immunosuppressive biomarker effects than PTC Therapeutics' Emflaza. Per management, the comparable cortisol suppression supports the currently approved Agamree dosing and suggests that patients switching from Emflaza to Agamree are unlikely to require additional dosing adjustments.

Part B enrolled 36 healthy volunteers who received Agamree at daily doses of 9, 27 or 40 mg/kg for seven days. Clinically relevant immunosuppressive effects were observed only at the highest Agamree dose, which exceeds currently approved and previously studied clinical dosing levels. No meaningful immunosuppressive effects were detected at the lower 9 mg/kg or 27 mg/kg doses. However, immune suppression became more pronounced with repeated dosing at 40 mg/kg and persisted after treatment ended.

Collectively, the data indicate that Agamree maintains glucocorticoid and anti-inflammatory activity while avoiding clinically meaningful immunosuppression at therapeutic doses. These findings strengthen Catalyst Pharmaceuticals' efforts to broaden Agamree's label into additional chronic inflammatory rare diseases while further differentiating the therapy from PTC Therapeutics’ Emflaza and other traditional corticosteroids.

CPRX is Set to be Acquired by Angelini Pharma in $4.1B DealCatalyst Pharmaceuticals’ pipeline progress comes as the company moves toward its planned acquisition by Angelini Pharma in a transaction valued at approximately $4.1 billion. Under the definitive agreement announced in May 2026, Angelini Pharma will acquire CPRX for $31.50 per share in cash, representing a 21% premium to the latter’s unaffected closing share price on April 22, 2026, the last trading day before market signs that the transaction had become public information. The deal has received unanimous approval from the boards of both companies and is expected to close during the third quarter of 2026, subject to shareholder and regulatory approvals.

The acquisition marks Angelini Pharma's entry into the U.S. market while expanding its rare disease and brain health portfolio. Following completion, Angelini plans to integrate Catalyst Pharmaceuticals’ commercial infrastructure and rare disease portfolio, including Agamree, Firdapse (approved for Lambert-Eaton myasthenic syndrome) and Fycompa (approved for epilepsy), with its existing neuroscience expertise. For CPRX, the transaction provides shareholders with immediate cash value while positioning its therapies for broader global commercialization and continued investment in rare disease development.

CPRX’s Zacks Rank & Stocks to ConsiderCatalyst Pharmaceuticals currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased from $1.50 to $3.02. Over the same period, EPS estimates for 2027 have also risen from $2.91 to $4.92. LQDA shares have surged 130% year to date.

Liquidia’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents, while the same for its 2027 EPS is currently pegged at 87 cents. IMCR shares have lost 8.9% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, with the average surprise being 46.66%.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

One company to watch right now is Par Pacific (PARR - Free Report) . PARR is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A.

Another notable valuation metric for PARR is its P/B ratio of 1.57. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.45. Over the past year, PARR's P/B has been as high as 1.63 and as low as 0.58, with a median of 0.80.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. PARR has a P/S ratio of 0.39. This compares to its industry's average P/S of 0.56.

These figures are just a handful of the metrics value investors tend to look at, but they help show that Par Pacific is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, PARR feels like a great value stock at the moment.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE: GPK) and certain of its former officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-03790, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Graphic Packaging securities between February 4, 2025 and February 2, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its former top officials.

If you are an investor who purchased or otherwise acquired Graphic Packaging securities during the Class Period, you have until July 6, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  

[Click here for information about joining the class action]

Graphic Packaging, together with its subsidiaries, designs, produces, and sells consumer packaging products.  Its customers include businesses in the food, foodservice, beverage, household, and other consumer product industries in the Americas, Europe, and the Asia Pacific.  The Company sells its products through sales offices, as well as through broker arrangements with third parties.

At all relevant times, Defendants touted the purported strength and stability of Graphic Packaging's business model and operations, as well as its purported ability to deliver on its cost and inventory reduction, free cash flow (FCF"), and profitability goals, notwithstanding ongoing and persistent market headwinds challenging the Company's and its customers' businesses.

Indeed, in February 2025, despite its President and Chief Executive Officer ("CEO"), Defendant Michael P. Doss ("Doss"), acknowledging "unusual volume challenges for the industry and our customers" over the past several years, Graphic Packaging forecasted full year ("FY") 2025 net sales, adjusted EBITDA, and adjusted earnings per share ("EPS") of $8.7 billion to $8.9 billion, $1.68 billion to $1.78 billion, and $2.53 to $2.78, respectively, excluding foreign exchange impacts.  Defendant Doss attributed the Company's ability to weather the aforementioned headwinds to its overall business model and operations, asserting that Defendants would continue to "build on" the Company's "consisten[t]" and "profit[able]" and "strong and steady" results in 2025.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (ii) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (iv) accordingly, the Company's previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on May 1, 2025, when Graphic Packaging issued a press release reporting its first quarter ("Q1") 2025 financial results.  Among other results, the press release reported Q1 non-GAAP EPS of $0.51, missing consensus estimates by $0.07, and revenue of $2.12 billion, representing a 6.2% year-over-year decline, and missing consensus estimates by $10 million.  The press release further revealed that the Company had negatively revised its previously issued FY 2025 net sales outlook to a range of $8.2 billion to $8.5 billion, significantly down from its prior guidance of $8.7 billion to $8.9 billion; its adjusted EBITDA outlook to a range of $1.4 billion to $1.6 billion, significantly down from its prior guidance of $1.68 billion to $1.78 billion; and its adjusted EPS outlook to a range of $1.75 to $2.25, significantly down from its prior guidance of $2.53 to $2.78.  The Company blamed the negatively revised guidance on "an expectation of a 2% volume decline and $80 million of input cost inflation at the midpoint", as well as "higher macroeconomic and consumer spending uncertainty."

On this news, Graphic Packaging's stock price fell $3.94 per share, or 15.57%, to close at $21.37 per share on May 1, 2025. 

On December 8, 2025, Graphic Packaging issued a press release announcing that it "plans to accelerate certain inventory reduction plans into the fourth quarter that were originally planned for 2026", and that "[p]roduction curtailment is expected to impact fourth quarter operating results by $15 million, which is in addition to the $15 million relating to" certain earlier-announced curtailments.  The Company further revealed that it had negatively revised its FY 2025 financial guidance again, now expecting its adjusted EBITDA "to be in the range of $1.38 billion to $1.43 billion"—significantly below its previously revised guidance of $1.4 billion to $1.45 billion—and adjusted EPS "to be in the range of $1.75 to $1.95"—significantly below its previously revised guidance of $1.80 to $2.00.

In a separate press release issued the same day, Graphic Packaging announced that Defendant Doss had "mutually agreed with [its] Board of Directors to step down from his role [as President and CEO] and as a director effective December 31, 2025."

Following these disclosures, Graphic Packaging's stock price fell $1.35 per share, or 8.66%, to close at $14.23 per share on December 9, 2025.

Then, on February 3, 2026, Graphic Packaging issued a press release reporting its fourth quarter ("Q4") and FY 2025 financial results.  Among other results, Graphic Packaging reported Q4 non-GAAP EPS of $0.29, missing consensus estimates by $0.06.  The Company attributed its disappointing Q4 2025 earnings results to, inter alia, lower volumes, increased costs, and inventory reduction.  Further, Graphic Packaging projected a meaningful decline in adjusted EBITDA in 2026, citing "a $130 million negative impact from actions taken to reduce inventory and generate [FCF], an approximately $100 million accrual (non-cash in 2026) for a return to more normal incentive compensation, January weather and production impacts, and other largely offsetting operating items."

In the same press release, Graphic Packaging's new President and CEO, Robbert Rietbroek, announced that he had "initiated a comprehensive review of our organization structure, operations, and footprint," among other aspects of the Company's business, thereby confirming the weakness and unsustainability of its present business model and operations.

On this news, Graphic Packaging's stock price fell $2.36 per share, or 15.97%, to close at $12.42 per share on February 3, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

Key Takeaways PDLB, CRDO, TILE, CIEN and CZFS passed screens for above-industry efficiency ratios and top Zacks Rank.The screen favors high inventory turnover, receivables turnover, asset utilization and operating margin. The five companies also posted positive average four-quarter earnings surprises ranging from 10.45% to 43.46%. Efficiency measures how well a company turns inputs into outputs and is a key indicator of its profit-generating potential. A company with a high efficiency level is expected to provide stellar returns, as it is believed to be positively correlated with price performance.

However, at times, it becomes difficult to measure the efficiency level of a company. This is why one must consider popular efficiency ratios while selecting stocks.

Ponce Financial Group (PDLB - Free Report) , Credo Technology Group (CRDO - Free Report) , Interface (TILE - Free Report) , Ciena (CIEN - Free Report) and Citizens Financial Services (CZFS - Free Report) made it through the screening process.

The efficiency ratios are:

Receivables Turnover: This is the ratio of 12-month sales to four-quarter average receivables. It shows a company’s potential to extend its credit and collect debt in terms of that credit. A high receivables turnover ratio, or the “accounts receivable turnover ratio” or “debtor’s turnover ratio” is desirable as it shows that the company is capable of collecting its accounts receivables or that it has quality customers.

Asset Utilization: This ratio indicates a company’s capability to convert assets into output and is thus a widely known measure of efficiency level. It is calculated by dividing total sales over the past 12 months by the last four-quarter average of total assets. Like the above ratios, high asset utilization may indicate that a company is efficient.

Inventory Turnover: The ratio of the 12-month cost of goods sold (COGS) to a four-quarter average inventory is considered one of the most popular efficiency ratios. It indicates a company’s ability to maintain a suitable inventory position. While a high value indicates that the company has a relatively low inventory level compared to COGS, a low value indicates that the company is facing declining sales, which has resulted in excess inventory.

Operating Margin: This efficiency measure is the ratio of operating income over the past 12 months to sales over the same period. It measures a company’s ability to control operating expenses. Hence, a high value of the ratio may indicate that the company manages its operating expenses more efficiently than its peers.

Screening CriteriaIn addition to the above-mentioned ratios, we have added a favorable Zacks Rank — Zacks Rank #1 (Strong Buy) — to the screen to make this strategy more profitable. You can see the complete list of today’s Zacks #1 Rank stocks here.

Inventory Turnover, Receivables Turnover, Asset Utilization, and Operating Margin greater than the industry average(Values of these ratios higher than industry averages may indicate that the efficiency level of the company is higher than its peers.)   

The use of these few criteria has narrowed down the universe of over 7,906 stocks to 15.

Our ChoicesHere are the top five stocks that made it through the screen:

Ponce Financial Group

Ponce Financial Group is the financial holding company for Ponce Bank. PDLB has an average four-quarter earnings surprise of 43.46%.

Credo Technology

Credo Technology offers high-speed connectivity solutions. CRDO has an average four-quarter earnings surprise of 27.35%.

Interface

Interface is the world's largest manufacturer of modular carpet. TILE has an average four-quarter earnings surprise of 26.75%.

Ciena

Ciena is a leading provider of optical networking equipment, software and services. CIEN has an average four-quarter earnings surprise of 19.45%.

Citizens Financial Services

Citizens Financial Services is the bank holding company for First Citizens National Bank. CZFS has an average four-quarter earnings surprise of 10.45%.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Calix, Inc. ("Calix" or the "Company") (NYSE: CALX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Calix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Calix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.   

[Click here for information about joining the class action]  

On April 21, 2026, after the market closed, Calix reported results for the first quarter of 2026 earnings, including that "[n]on-GAAP gross margin was 57.2%, a decrease of 80 basis points sequentially."  Further, the Company reported gross margin guidance for the second quarter of 2026 is "55.8% (at the midpoint) is down 140 basis points from the previous quarter.  This decline is primarily due the increase in memory component costs."  In an accompanying earnings call on the same day, Calix's Chief Financial Officer, Cory Sindelar, said that "advanced purchasing had allowed us to avoid higher memory component costs during the first quarter.  However, that advanced supply has run its course, and we now face market prices."  Sindelar further revealed that, "reflecting the effects of higher memory component costs," "[f]or the year, we expect our non-GAAP gross margin to decline between 50 and 150 basis points." 

On this news, Calix's stock price fell $6.93 per share, or 13.98%, to close at $42.65 per share on April 22, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

John Rogers Jr., founder of Ariel Investments, has built a four-decade track record buying quality but unloved mid- and small-cap consumer names, then holding them through years of doubt. His playbook prizes recognizable brands, durable cash flow, and disciplined capital return, purchased when Wall Street has given up. Ariel’s logo is a tortoise for a reason: slow and steady wins.

For retirement-focused investors, the Rogers philosophy is appealing, but the wrapper matters more than the sticker. Three current Rogers-style candidates are all out of favor for very different reasons. The real question is which kind of out-of-favor a retiree can actually live with. We rank them from least to most appropriate for a long-horizon income portfolio.

3. Mohawk Industries Mohawk Industries (NYSE:MHK | MHK Price Prediction) is the world’s largest flooring company, home to Daltile, Karastan, Pergo, and Quick-Step. It is also the textbook Rogers pick: shares trade near $120, down almost 39% over five years, on a trailing P/E of 18x and a price-to-book ratio of 0.88.

Q1 FY26 revenue rose to $2.73 billion with adjusted EPS of $1.90, beating the $1.81 estimate. CEO Jeff Lorberbaum flagged that “the global flooring industry has been in a recession for almost four years, and historically we have multiple years of higher growth as markets recover.” Housing starts in May 2026 came in at 1,177 thousand units, still in the healthy range but well off the March 2026 peak of 1,522 thousand.

The problem for retirees: Mohawk pays no dividend, has a beta of 1.21, and the thesis rests entirely on a housing cycle turn that could take years. Big upside if it works, but no income while you wait.

2. Mattel Mattel (NASDAQ:MAT) owns Barbie, Hot Wheels, Fisher-Price, and UNO. The stock has been punished, trading near $13.50, down about 32% year to date and over 57% over the past decade, near the 52-week low of $13.37.

Q1 FY26 revenue of $862.2 million topped estimates by 6.58%, with Hot Wheels billings up 17%. Management repurchased $200 million of stock in Q1 and is targeting $400 million in buybacks for 2026 under a new $1.5 billion authorization through 2028. Full-year adjusted EPS guidance is $1.27 to $1.39, and the shares trade at a forward P/E near 10x. Analysts have an $18.50 consensus target.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and General Mills didn't make the cut. Grab the names FREE today.

CEO Ynon Kreiz had a Masters of the Universe film hit theaters on June 5, 2026, plus a gaming push. For a retiree, though, Mattel pays no dividend, and toys are discretionary. It ranks ahead of Mohawk because iconic IP and heavy buybacks provide harder downside support than a housing cycle bet.

1. General Mills General Mills (NYSE:GIS) owns Cheerios, Blue Buffalo, Häagen-Dazs, and Pillsbury. The stock is itself unloved, trading near $37.50, about 31% lower over the past year, on a trailing P/E of 9x with a beta of negative 0.04.

The Q4 FY26 report on July 1, 2026, delivered adjusted EPS of $0.95, crushing the $0.80 estimate, on revenue of $4.61 billion. Management reaffirmed a $3 billion cumulative cost-savings target by FY2030 and guided free cash flow conversion near 85%.

The dividend is the anchor. General Mills declared a $0.61 quarterly payout on July 1, 2026, payable August 3, 2026, with an uninterrupted history stretching back through the 2008 crisis and a current yield of 6.5%. Food spending hit $1,566.8 billion in May 2026, up from $1,518.3 billion a year earlier, even as consumer sentiment slid to 44.8, near recessionary levels. Risks include a $1.8 billion goodwill impairment on the North America Pet segment and a softer FY27 profit outlook.

The Rogers Verdict for Retirees Rogers’s philosophy is about buying quality brands during maximum pessimism and waiting. All three names qualify. But retirement portfolios weigh income reliability and volatility more heavily than upside optionality. Mohawk offers the biggest recovery torque and no cash return. Mattel adds iconic IP and aggressive buybacks, still without a dividend. General Mills pairs a beaten-down valuation with a 27-year dividend record, a defensive beta near zero, and cash flows tied to grocery aisles that shoppers fill regardless of the sentiment index. For a long-horizon retiree looking for the Rogers tortoise pace with a paycheck attached, General Mills is the fit.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and General Mills didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In FS KKR Capital To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in FS KKR Capital between May 8, 2024 and February 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FS KKR Capital Corp. ("FS KKR Capital" or the "Company") (NYSE: FSK) and reminds investors of the July 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company's portfolio valuation process; (3) the Company overstated the durability of its quarterly distribution strategy; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding FS KKR Capital's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the FS KKR Capital Corp. class action, go to www.faruqilaw.com/FSK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the FS KKR Capital Corp. Securities Class Action Lawsuit:

What is the FS KKR Capital securities fraud lawsuit about?
The FS KKR Capital securities fraud lawsuit is a federal securities class action alleging that FS KKR Capital Corp. (NYSE: FSK) and its executives made false and misleading statements to investors by overstating the effectiveness of its portfolio restructuring efforts for nonaccrual companies, overstating the valuation of its portfolio investments, and overstating the durability of its quarterly distribution strategy. As the truth emerged through a series of disclosures — including an August 6, 2025 report revealing a 6.2% decline in net asset value, a $474 million drop in total fair value of investments, and a loss per share of negative $0.75, followed by a February 25, 2026 announcement of further NAV deterioration, an additional $406 million decline in investment fair value, a dividend cut from $0.70 to $0.48 per share, and an acknowledgment that identified problem companies accounted for only 50% of net realized and unrealized losses — FSK's stock price dropped sharply, causing significant losses for investors.

Who may be eligible to participate in the FS KKR Capital class action lawsuit?
Investors who purchased or acquired FS KKR Capital Corp. (FSK) stock between May 8, 2024 and February 25, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the FS KKR Capital securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former FS KKR Capital employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the FS KKR Capital lawsuit?
A lead plaintiff in the FS KKR Capital class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any FS KKR Capital investor who purchased FSK stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased FS KKR Capital stock during the Class Period?
Investors who purchased FS KKR Capital Corp. (FSK) stock between May 8, 2024 and February 25, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the FS KKR Capital securities class action is July 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/FSK for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FS KKR Capital Corp. ("FSK KRR" or the "Company") (NYSE: FSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether FSK KRR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have July 3, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired FSK KRR securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.   

[Click here for information about joining the class action]  

On August 6, 2025, the Company reported second quarter 2025 earnings, revealing that the Company's net asset value had declined to $21.93 per share, down $1.44, or 6.2% from the prior quarter, and the total fair value of investments fell $474 million, to $13,648 million.  Moreover, the Company report earnings (loss) per share of negative $0.75, down $1.18 or 274.4% from the prior quarter, and a total net realized and unrealized loss per share of negative $1.36, down $1.12 or 466.7% from the prior quarter.  Further, investments on non-accrual status rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter.  

On this news, FS KKR's stock price fell $1.66 per share, or 8.2%, to close at $18.58 per share on August 7, 2025. 

Then, on February 25, 2026, the Company announced fourth quarter and full year 2025 earnings, revealing net asset value had continued to decline to $20.89, down $1.10 or 5% from prior quarter, and the total fair value of investments fell another $406 million, to $13,009 million.  Moreover, the Company reported earnings (loss) per share of negative $0.41, down $1.17 or 153.9% from the prior quarter, and a total net realized and unrealized loss per share of negative $0.89, down $1.08 or 568.421% from the prior quarter.  Further, investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter.  The Company also "acknowledge[d] specific challenges" with additional companies and cut its dividend to $0.48 per share (previously $0.70). 

On this news, FS KKR's stock price fell $2.03 per share, or 15.24%, to close at $11.29 per share on February 26, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

Equinix (EQIX 0.53%) may look like a data-center REIT, but the real story could be its interconnection moat. As enterprise AI moves from experiments into production, companies may need secure physical locations to connect data, clouds, networks, and AI models. That could make Equinix a quiet winner in AI infrastructure.

Stock prices used were the market prices of June 23, 2026. The video was published on July 1, 2026.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Equinix. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Trane Technologies (TT - Free Report) Founded in 1885 and headquartered in Swords, Ireland, Trane Technologies is a designer, manufacturer, seller and servicer of climate control products for HVAC and transport solutions. The company distributes its products through branch sales offices, dealers and distributors in the United States and through subsidiary sales and service companies in other parts of the world. Trane generated around 81% of its revenues from the United States and the rest from more than 100 other countries. With no customer accounting for more than 10% of revenues, the company’s business does not suffer on account of any single customer of group of customers.

TT is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. TT has a Growth Style Score of B, forecasting year-over-year earnings growth of 13.6% for the current fiscal year.

For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $14.84 per share. TT boasts an average earnings surprise of +2.7%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, TT should be on investors' short list.

Alert: Claims Focus on Alleged Misrepresentations About Badger Meter's AMI Transition and Short-Cycle Municipal Ordering Practices

, /PRNewswire/ -- SueWallSt reminds purchasers of Badger Meter, Inc. (NYSE: BMI) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased BMI securities between April 18, 2024 and April 16, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

Badger Meter shares lost $36.75 per share, a decline exceeding 24%, on April 17, 2026, after the company disclosed that total sales fell 9% year-over-year and utility water revenue dropped 10%. Investors have until August 3, 2026 to seek lead plaintiff status.

How a Water Meter Company Allegedly Disguised Depleted Demand as Growth

A water measurement company cannot sustain reported growth rates when its near-term order pipeline is thinning. The complaint contends that Badger Meter's transition from traditional mechanical meters into advanced metering infrastructure (AMI) solutions created two distinct revenue channels: "short-cycle" municipal replacement orders that convert to revenue quickly, and "long-cycle" AMI deployment projects spanning multiple years. The filing states that management exploited this dual structure to mask deteriorating short-cycle demand behind the long-cycle backlog, presenting a picture of broad-based, durable growth to investors.

Alleged Short-Cycle Ordering Manipulation by the Numbers

The action claims that the operational reality diverged sharply from management's public narrative:

Short-cycle municipal ordering softness produced approximately $15 million to $20 million in lower revenue versus internal expectations for 1Q 2026 Utility water sales declined 10% year-over-year in 1Q 2026 after a 6% sequential decline in 4Q 2025 Operating profit margins contracted from 22.2% to 17.4% in a single year, a 480 basis-point collapse Diluted EPS fell from $1.30 to $0.93, a 28% year-over-year decline Total sales of $202.3 million in 1Q 2026 trailed the prior year's $222.2 million by $19.9 million The AMI Project Timing Shield

As detailed in the action, when 2Q 2025 results disappointed, the company attributed the shortfall to AMI projects wrapping up and delays in new project starts. This framing, the complaint alleges, functioned as a shield: by pointing to the lumpy, project-driven nature of AMI deployments, the company deflected attention from the more fundamental problem of weakening short-cycle municipal demand. The lawsuit chronicles that this "project pacing" explanation was repeated through 4Q 2025, even as sequential utility water revenue continued to erode.

Only in April 2026 did management acknowledge that short-cycle variability "has always existed" but had been "less visible" due to backlog conditions, the complaint asserts.

Calculate your potential recovery or call (888) SueWallSt.

"The complaint raises serious questions about whether investors received accurate information regarding the sustainability of Badger Meter's revenue channels and the true health of its short-cycle municipal ordering pipeline." -- Joseph E. Levi, Esq.

Start your claim now or contact Joseph E. Levi, Esq. at (888) SueWallSt.

SueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the BMI Lawsuit

Q: Who is eligible to join the BMI investor lawsuit? A: Investors who purchased BMI stock or securities between April 18, 2024 and April 16, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What specific misstatements does the BMI lawsuit allege? A: The complaint alleges Badger Meter made materially false or misleading statements regarding the durability of customer demand, the drivers of record financial results, and the absence of order pull-forward activity during the class period. When the true state of short-cycle demand was revealed, the stock price declined sharply.

Q: What do BMI investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my BMI shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

SOURCE SueWallSt.com

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Badger Meter To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Badger Meter between April 18, 2024 and April 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Badger Meter, Inc. ("Badger Meter" or the "Company") (NASDAQ: BMI) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that Badger Meter's strong financial results reflected "ongoing favorable industry trends," "secular growth drivers," and "solid operating execution." They likewise touted "strong" demand and said they were seeing "robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth," and that Badger Meter possessed a "long runway" for growth.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Badger Meter's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Badger Meter class action, go to www.faruqilaw.com/BMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Badger Meter Securities Class Action Lawsuit:

What is the Badger Meter securities fraud lawsuit about?
The Badger Meter securities fraud lawsuit is a federal securities class action alleging that Badger Meter, Inc. (NASDAQ: BMI) and its executives made false and misleading statements to investors by touting "strong" demand, a "robust" order pipeline, and a "long runway" for growth while concealing that the Company's financial results were not sustainable. As the truth emerged through a series of disclosures — including disappointing Q2 2025 results and a sequential sales decline forecast on July 22, 2025, missed revenue expectations and a 6% sequential decline in utility water sales on January 28, 2026, and Q1 2026 earnings that missed consensus estimates by $0.26 per share with revenue missing by $28.58 million on April 17, 2026 — BMI's stock price dropped sharply, causing significant losses for investors.

Who may be eligible to participate in the Badger Meter class action lawsuit?
Investors who purchased or acquired Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Badger Meter securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Badger Meter employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Badger Meter lawsuit?
A lead plaintiff in the Badger Meter class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Badger Meter investor who purchased BMI stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Badger Meter stock during the Class Period?
Investors who purchased Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Badger Meter securities class action is August 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/BMI for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

LOS ANGELES, July 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Badger Meter, Inc. (“Badger” or “the Company”) (NYSE: BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between April 18, 2024 and April 16, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 3, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Badger Meter claimed its financial performance was based on “secular growth drivers,” and “solid operating execution.” The Company touted “strong” demand and a “long runway” for growth. In truth, the Company’s performance was partially based on pulling forward customer orders to recognize revenue early. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Badger Meter, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 The Schall Law Firm

Key Takeaways Onto Innovation is gaining from AI demand, advanced packaging and HBM manufacturing growth.ONTO sees growth from Dragonfly G5, Atlas G6 and expanding advanced packaging applications.ONTO trades above industry valuation, while estimates for 2026 and 2027 have moved higher. Shares of Onto Innovation, Inc. (ONTO - Free Report) have surged 25.5% over the past month compared with the Zacks Nanotechnology industry’s growth of 24.7%. The company has outpaced the Zacks Computer and Technology sector and the S&P 500 composite’s plunge of 4.3% and 0.9%, respectively. The rally reflects growing investor optimism surrounding the company's exposure to AI, advanced semiconductor packaging and HBM manufacturing. As chipmakers continue to invest aggressively to meet demand for AI infrastructure, Onto Innovation has emerged as one of the beneficiaries of this trend.

Image Source: Zacks Investment Research

ONTO’s key competitors include KLA Corporation (KLAC - Free Report) , Camtek Ltd (CAMT - Free Report) and Nova Ltd. (NVMI - Free Report) . KLAC has grown 25.3%, while CAMT and NVMI plummeted 15.2% and 5.2%, respectively, in the same time frame.  

After such a sharp move, however, investors naturally face an important question: Is it still worth buying ONTO, or has the rally already priced in most of the good news? Let's examine what's driving the stock higher, the company's long-term prospects and whether investors should buy, hold, or wait for a better entry point.

Advanced Packaging Becomes a Major Growth Driver for ONTOThe company sees high growth potential in advanced packaging, silicon photonics, panel-level packaging and related applications. Advanced packaging is expected to grow more than 50% in 2026, driven by the rapid expansion of AI and next-generation semiconductor technologies. Silicon photonics is already moving into volume production as AI servers require faster data transfer and lower power consumption. The panel-level packaging market, currently valued at roughly $200 million, also has significant room for expansion as the industry increasingly adopts panel-based manufacturing and chiplet architectures.

At the same time, demand for smaller and denser interconnects, with bump sizes below 6 microns, continues to rise, creating additional opportunities across the advanced packaging ecosystem. Despite ongoing supply chain headwinds, lead times remain well-managed, and companies have reported no major impact on customer commitments or delivery schedules. Onto Innovation sees a strong growth runway in the 2.5D logic market, supported by deeper engagement with a key customer and an expanding set of applications. Previous system limitations have been removed, enabling the company to pursue more than 15 applications that were previously out of reach, expanding its serviceable addressable market.

Management also indicated that its current outlook may be conservative, leaving room for upside in the second half of the year, with the momentum expected to extend into 2027 as customer adoption broadens. At the same time, the company is benefiting from a more diversified customer base, as advanced packaging customers increasingly outsource high-value process steps. By strengthening its position with outsourced manufacturing partners, ONTO is reducing customer concentration, expanding its market reach and building a more diversified and sustainable long-term revenue base.

ONTO continues strengthening its competitive edge through multiple product wins and market expansion efforts. Its Dragonfly G5 inspection system has been qualified by a top 2.5D logic customer, with shipments already ahead of schedule and demand expected to grow through 2026. Further, the Atlas G6 platform is gaining momentum in advanced-node manufacturing, with management predicting 25% growth in 2026. A new through-silicon via metrology application is set for initial shipments in the second half of 2026.

Image Source: Zacks Investment Research

For 2027, it anticipates outpacing wafer fab equipment industry growth through ongoing market share gains, driven by Dragonfly G5's nearly $1 billion addressable market, the continued expansion of Atlas G6 in gate-all-around applications, new surface charge metrology and panel-level packaging offerings and a strong pipeline of new applications for a wider customer base.

Risks Faced By ONTODespite its strong long-term prospects, Onto Innovation faces several risks. The semiconductor equipment industry remains highly cyclical, making customer spending vulnerable to shifts in inventory levels and end-market demand. The company also relies on a handful of large semiconductor customers, leaving results exposed to delays in capital spending. In addition, export controls and geopolitical tensions continue to create uncertainty for semiconductor equipment suppliers, potentially limiting future growth opportunities. Intense competition from larger industry players further pressures Onto Innovation to continue heavy R&D investments to maintain its technological edge.

Favorable Estimate Revision Trend for ONTOEarnings estimates for ONTO have moved up for both 2026 and 2027 over the past 60 days.

Image Source: Zacks Investment Research

Is ONTO’s Valuation Becoming Stretched?Valuation is the primary concern after ONTO's 26% rally, with semiconductor equipment stocks typically trading at rich multiples during upcycles. In terms of forward price/earnings, ONTO’s shares are trading at 41X, higher than the industry’s 8.05X.

Image Source: Zacks Investment Research

KLAC, CAMT and NVMI are trading at multiples of 71.69X, 43.13X and 47.12X, respectively.

Should Investors Buy, Hold or Fold ONTO Stock?Onto Innovation has become one of the more compelling semiconductor equipment companies benefiting from the AI boom. The recent rally reflects investors' growing confidence in these opportunities, but it also raises valuation expectations. While the stock may experience near-term volatility after such a sharp advance, the company's long-term fundamentals remain solid.

For existing shareholders, the recent surge reinforces the strength of Onto Innovation's business model and supports a hold stance, particularly for those with a multi-year investment horizon. For prospective investors, the company remains attractive, but initiating a position gradually or waiting for a pullback could offer a more balanced entry point.

ONTO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Symbotic Inc. (SYM - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this company have returned -4.8%, compared to the Zacks S&P 500 composite's -1.4% change. During this period, the Zacks Technology Services industry, which SYMBOTIC INC falls in, has lost 4.7%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

SYMBOTIC INC is expected to post earnings of $0.12 per share for the current quarter, representing a year-over-year change of +340%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $0.5 for the current fiscal year indicates a year-over-year change of -72.5%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $0.63 indicates a change of +25.8% from what SYMBOTIC INC is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, SYMBOTIC INC is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For SYMBOTIC INC, the consensus sales estimate for the current quarter of $714.76 million indicates a year-over-year change of +20.7%. For the current and next fiscal years, $2.79 billion and $3.62 billion estimates indicate +24.1% and +30% changes, respectively.

Last Reported Results and Surprise HistorySYMBOTIC INC reported revenues of $676.48 million in the last reported quarter, representing a year-over-year change of +23.1%. EPS of $0.44 for the same period compares with -$0.04 a year ago.

Compared to the Zacks Consensus Estimate of $660.6 million, the reported revenues represent a surprise of +2.4%. The EPS surprise was +300%.

Over the last four quarters, SYMBOTIC INC surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

SYMBOTIC INC is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about SYMBOTIC INC. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.

On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.

One stock to keep an eye on is Eastman Chemical (EMN - Free Report) . EMN is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 9.55. This compares to its industry's average Forward P/E of 12.70. Over the past year, EMN's Forward P/E has been as high as 13.09 and as low as 7.66, with a median of 10.44.

Investors should also recognize that EMN has a P/B ratio of 1.27. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. EMN's current P/B looks attractive when compared to its industry's average P/B of 2.06. Within the past 52 weeks, EMN's P/B has been as high as 2.33 and as low as 1.14, with a median of 1.74.

These figures are just a handful of the metrics value investors tend to look at, but they help show that Eastman Chemical is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, EMN feels like a great value stock at the moment.

Key Takeaways U.S. markets hit record highs as AI worries eased and the Iran-U.S. war appeared near resolution.STRL has soared 239.5% over the past year but lost 10.5% over the past week.STX and SMTC surged over the past year but declined last week, with strong Momentum Scores. Over the past few days, the broader U.S. equity markets scaled record-high territories as concerns related to AI abated and the Iran-U.S. war appeared to be nearing a resolution. Riding on solid performances by blue-chip firms, the markets recorded one of the best first-half performances in recent memory. With the United States and Iran agreeing to hit the pause button on war skirmishes and allow the free passage of commercial vessels through the Strait of Hormuz, the rally is likely to have a longer run.

The spotlight is now on the Federal Reserve Chairman Kevin Warsh as investors look for cues to the monetary policy and gauge an idea of the future stock market direction. Amid the vagaries of the market, investors often seek to employ time-tested winning strategies to fetch sustained profits. One of the most successful game plans to beat the blues is to bet on momentum stocks, like Sterling Infrastructure, Inc. (STRL - Free Report) , Seagate Technology Holdings plc (STX - Free Report) and Semtech Corporation (SMTC - Free Report) when value or growth investing fails to generate the desired profits.

    This approach primarily tends to follow the adage, “the trend is your friend.” At its core, momentum investing is “buying high and selling higher.” It is based on the idea that once a stock establishes a trend, it is more likely to continue in that direction because of the momentum that is already behind it. Momentum investing is a way to profit from the general human tendency to extrapolate current trends into the future. It is based on that gap in time before the mean reversion occurs, i.e., before prices become rational again.

Momentum strategies have been known to be alpha-generative over a long period and across market stages. Therefore, this strategy is quite tricky to implement, as detecting these trends is not easy. Here, we have created a strategy to help investors get in on these fast movers and rake in handsome gains. Our screen will help you benefit from long-term price momentum and a short-term pullback in price.

Screening Parameters for Momentum Anomaly StocksPercentage Change in Price (52 Weeks) = Top #50: This selects the top 50 stocks with the best percentage price change over the last 52 weeks. This parameter ensures we get the best stocks that have appreciated steadily over the past year.

Percentage Change in Price (1 Week) = Bottom #10: From the above 50 stocks, we then choose those that are also among the 10 worst performers over a short one-week period. This parameter picks the ones that have witnessed a short-term pullback in price.

Zacks Rank #1: Stocks sporting a Zacks Rank #1 (Strong Buy) have a proven history of outperformance irrespective of the market conditions. You can see the complete list of today’s Zacks #1 Rank stocks here.

Momentum Style Score of B or Better: A top Momentum Style Score knocks out a lot of the screening process, as it takes into account several factors that include volume change and performance relative to its peers. It indicates when the timing is best to grab a stock and take advantage of its momentum with the highest probability of success. Stocks with a Momentum Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), handily outperform other stocks.

Current Price Greater Than $5: The stocks must all be trading at a minimum of $5.

Market Capitalization = Top #3000: We have chosen stocks that are among the top 3000 in terms of market value to ensure the stability of price.

Average 20-Day Volume Greater Than 100,000: A substantial trading volume ensures that these stocks are easily tradable.

Here are three of the seven stocks that made it through this screen:

Headquartered in The Woodlands, TX, Sterling is a diversified U.S. infrastructure services company that develops and services critical infrastructure while focusing on large and complex projects. It operates across the Southern, Northeastern, Mid-Atlantic, Rocky Mountain regions and Pacific Islands.

The stock has soared 239.5% over the past year but lost 10.5% over the past week. Sterling has a Momentum Score of A.

Headquartered in Dublin, Ireland, Seagate is a leading provider of data storage technology and infrastructure solutions. The company’s primary product offering is hard disk drives, which are commonly referred to as disk drives, hard drives or HDDs. These are used as the primary medium for storing digitally encoded data on rapidly rotating disks with magnetic surfaces.

The stock has surged 502.3% over the past year but declined 7.9% over the past week. Seagate has a Momentum Score of A.

Headquartered in Flynn Road, Camarillo, CA, Semtech designs, manufactures and markets a wide range of analog and mixed-signal semiconductors for commercial applications. The company's devices are used in a variety of applications, including computer, communications, industrial, military-aerospace and automotive. The company also provides a limited amount of wafer foundry services to other electronic component manufacturers.

The stock has surged 234.5% in the past year but declined 7.2% in the past week. Semtech has a Momentum Score of B.

Abercrombie & Fitch (ANF - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this teen clothing retailer have returned +20.8% over the past month versus the Zacks S&P 500 composite's -1.4% change. The Zacks Retail - Apparel and Shoes industry, to which Abercrombie belongs, has lost 1.6% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Abercrombie is expected to post earnings of $1.94 per share, indicating a change of -16.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -0% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $10.61 points to a change of +7.6% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $11.65 indicates a change of +9.8% from what Abercrombie is expected to report a year ago. Over the past month, the estimate has changed +0.5%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abercrombie.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Abercrombie, the consensus sales estimate for the current quarter of $1.25 billion indicates a year-over-year change of +3.2%. For the current and next fiscal years, $5.46 billion and $5.7 billion estimates indicate +3.7% and +4.5% changes, respectively.

Last Reported Results and Surprise HistoryAbercrombie reported revenues of $1.11 billion in the last reported quarter, representing a year-over-year change of +1.5%. EPS of $1.47 for the same period compares with $1.59 a year ago.

Compared to the Zacks Consensus Estimate of $1.12 billion, the reported revenues represent a surprise of -0.48%. The EPS surprise was +16.67%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Abercrombie is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abercrombie. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

One company to watch right now is Arrow Electronics (ARW - Free Report) . ARW is currently sporting a Zacks Rank #1 (Strong Buy), as well as a Value grade of A. The stock holds a P/E ratio of 9.44, while its industry has an average P/E of 14.76. Over the past year, ARW's Forward P/E has been as high as 11.05 and as low as 8.04, with a median of 9.71.

Investors should also note that ARW holds a PEG ratio of 0.46. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ARW's PEG compares to its industry's average PEG of 0.49. Within the past year, ARW's PEG has been as high as 0.55 and as low as 0.40, with a median of 0.49.

Investors should also recognize that ARW has a P/B ratio of 0.98. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.13. Within the past 52 weeks, ARW's P/B has been as high as 1.22 and as low as 0.78, with a median of 1.02.

Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. ARW has a P/S ratio of 0.32. This compares to its industry's average P/S of 0.48.

Finally, investors will want to recognize that ARW has a P/CF ratio of 9.63. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 18.54. Over the past 52 weeks, ARW's P/CF has been as high as 11.55 and as low as 8.13, with a median of 10.03.

Investors could also keep in mind Avnet (AVT - Free Report) , another Electronics - Parts Distribution stock with a Zacks Rank of #2 (Buy) and Value grade of A.

Shares of Avnet are currently trading at a forward earnings multiple of 10.47 and a PEG ratio of 0.36 compared to its industry's P/E and PEG ratios of 14.76 and 0.49, respectively.

Over the past year, AVT's P/E has been as high as 16.75, as low as 8.05, with a median of 10.50; its PEG ratio has been as high as 1.89, as low as 0.35, with a median of 0.81 during the same time period.

Avnet sports a P/B ratio of 0.89 as well; this compares to its industry's price-to-book ratio of 2.13. In the past 52 weeks, AVT's P/B has been as high as 1.00, as low as 0.71, with a median of 0.91.

Value investors will likely look at more than just these metrics, but the above data helps show that Arrow Electronics and Avnet are likely undervalued currently. And when considering the strength of its earnings outlook, ARW and AVT sticks out as one of the market's strongest value stocks.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Considering buying SKYW stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Nu Holdings Ltd. (NU - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this company have returned +15%, compared to the Zacks S&P 500 composite's -1.4% change. During this period, the Zacks Banks - Foreign industry, which Nu falls in, has gained 7.3%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Nu is expected to post earnings of $0.20 per share, indicating a change of +42.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $0.83 for the current fiscal year indicates a year-over-year change of +33.9%. This estimate has changed -0.5% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $1.15 indicates a change of +38.1% from what Nu is expected to report a year ago. Over the past month, the estimate has changed -0.2%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Nu .

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Nu , the consensus sales estimate of $5.33 billion for the current quarter points to a year-over-year change of +45.2%. The $21.89 billion and $27.26 billion estimates for the current and next fiscal years indicate changes of +38.8% and +24.6%, respectively.

Last Reported Results and Surprise HistoryNu reported revenues of $4.97 billion in the last reported quarter, representing a year-over-year change of +53%. EPS of $0.19 for the same period compares with $0.12 a year ago.

Compared to the Zacks Consensus Estimate of $4.97 billion, the reported revenues represent a surprise of -0.01%. The EPS surprise was -5%.

Over the last four quarters, Nu surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Nu is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Nu . However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Wall Street analysts expect Levi Strauss (LEVI - Free Report) to post quarterly earnings of $0.24 per share in its upcoming report, which indicates a year-over-year increase of 9.1%. Revenues are expected to be $1.52 billion, up 4.8% from the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

In light of this perspective, let's dive into the average estimates of certain Levi Strauss metrics that are commonly tracked and forecasted by Wall Street analysts.

The consensus estimate for 'Total Levi?s Brands Net Revenues' stands at $1.48 billion. The estimate points to a change of +4.8% from the year-ago quarter.

The consensus among analysts is that 'Geographic Revenues- Americas' will reach $778.61 million. The estimate indicates a year-over-year change of +4.1%.

It is projected by analysts that the 'Geographic Revenues- Europe' will reach $422.36 million. The estimate suggests a change of +4.8% year over year.

The collective assessment of analysts points to an estimated 'Geographic Revenues- Asia' of $274.89 million. The estimate indicates a change of +6.5% from the prior-year quarter.

View all Key Company Metrics for Levi Strauss here>>>

Over the past month, Levi Strauss shares have recorded returns of +8.3% versus the Zacks S&P 500 composite's -1.4% change. Based on its Zacks Rank #2 (Buy), LEVI will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Intuitive Machines upgraded to Buy as operational risks have eased and strategic positioning has improved post-Lanteris acquisition. LUNR's Q1 2026 revenue surged to $186.7M, with the first positive adjusted EBITDA; backlog visibility and recurring NASA demand now support a more investable thesis. The NASA $148.3M award validates LUNR's evolution from lunar delivery to a broader cislunar infrastructure platform, enhancing long-term growth prospects.

Key Takeaways COHU has surged in 2026 as orders, chip-test utilization and AI demand confidence improve.First-quarter revenues rose 29.3% to $125.1M, but earnings missed as expenses stayed elevated.COHU's valuation is above industry and its five-year median, leaving less room for missteps. Cohu, Inc. (COHU - Free Report) has moved from a recovery candidate to a high-expectation semiconductor equipment stock. After a sharp 2026 rally, the debate is less about whether demand is improving and more about how much of that improvement is already reflected in the share price.

The stock still has support from AI, high-performance computing and improving order trends. Yet profitability remains early in its recovery, and valuation now leaves less room for execution errors.

COHU Has Momentum but Not a Clean StoryCOHU shares have surged 195.5% year to date and 236.2% over the past 12 months. That move reflects a better order backdrop, higher semiconductor test utilization and stronger confidence in AI-related demand.

COHU One-Year Price Return Performance
Image Source: Zacks Investment Research

The operating story, however, is still rebuilding. Cohu is benefiting from higher customer engagement in AI compute, HBM inspection and power-management test, but the company is recovering from a weak 2025 earnings base rather than compounding from already-strong profitability.

Teradyne, Inc. (TER - Free Report) is a useful comparison because it also serves semiconductor and electronics testing markets. Teradyne designs and manufactures automated test equipment, making it relevant for investors evaluating the broader chip-test cycle.

Advantest Corporation (ATEYY - Free Report) is another relevant benchmark in semiconductor test equipment. Its products include SoC, power-device and memory test systems, which overlap with several demand areas influencing Cohu’s opportunity set.

Cohu Revenue Growth Looks Better Than EarningsFirst-quarter 2026 revenues increased 29.3% year over year to $125.1 million, while non-GAAP gross margin improved to 46.5%. The quarter also benefited from stronger orders and estimated test-cell utilization of 78%.

Earnings were less convincing. Cohu reported non-GAAP earnings per share of a penny, missing expectations, while operating expenses remained elevated as the company increased investments to support high-performance computing opportunities.

The annual earnings picture also argues for patience. EPS was negative in 2025 at 22 cents per share, and the 2026 estimate calls for a recovery to 60 cents. That is progress, but not enough to make the earnings case look fully de-risked.

COHU Valuation Leaves Less Room for ErrorValuation is the main reason to be more measured after the rally. COHU trades at 5.29X forward 12-month sales, above the Zacks Electronics - Manufacturing Machinery industry’s 4.42X and well above its own five-year median of 2.20X.

COHU Forward 12-Month P/S Ratio
Image Source: Zacks Investment Research

That premium may be justified if AI and HPC demand converts into sustained revenue growth. Still, a richer sales multiple increases the penalty if customer qualifications, order timing or margin recovery disappoint.

The valuation signal is also visible in the price target. The $78 target sits only modestly above the $69.11 stock price as of July 1, 2026, suggesting upside exists but is no longer wide after the rally.

Cohu Balance Sheet Supports the Bull CaseCohu’s balance sheet remains a clear support for the bullish argument. The company ended the first quarter of 2026 with $488.7 million in cash and investments.

That financial flexibility matters because the recovery depends on sustained product development and customer qualifications. With roughly $305 million of total debt, Cohu has room to fund R&D, production capacity and software development while waiting for broader semiconductor demand to scale.

How COHU Screens for Investors NowThe bottom line is that COHU still offers upside tied to AI compute, HBM inspection and a cyclical recovery, but the stock no longer looks inexpensive. The rally has made execution and valuation discipline more important.

COHU currently carries a Zacks Rank #2 (Buy), indicating supportive near-term earnings estimate trends. That helps keep the stock on investors’ watchlists, especially while orders and revenue are improving. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Style Scores are more mixed. COHU has a Growth Score of B, but its Value Score of F, Momentum Score of F and VGM Score of F point to an uneven overall setup. For investors, that combination supports a selective stance: the recovery story is real, but valuation and execution risks argue against chasing the stock without caution.